A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

INTRODUCTION: Data for the use of rituximab, gemcitabine, and oxaliplatin (R-GemOx) for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R-GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record-derived database comprising patient-level data primarily from US community oncology practices. METHODS: Patients diagnosed with LBCL who initiated treatment with R-GemOx in the second or later line of therapy between 2011 and 2023, were included. Patient characteristics, treatment patterns, and efficacy outcomes were assessed. RESULTS: Of 281 patients, most (66.2%) were treated at community centers. Overall response rate was 45.4% (95% confidence interval [CI]: 38.1-52.9); complete response (CR) rate was 22.2% (95% CI: 16.4-28.8). Median progression-free and overall survival (OS) were 2.8 months (95% CI: 2.6-3.7) and 12.7 months (95% CI: 10.6-17.1), respectively. In patients who received R-GemOx in the second line, the CR rate was higher and the median OS was longer versus those who received it in later lines (CR rate, 26.3% vs. 17.4%; median OS, 19.6 vs. 10.0 months, respectively). CONCLUSION: These data offer a real-world benchmark for patterns of use and outcomes of R-GemOx in patients with R/R LBCL in the United States. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.